Clinical trial
An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection/Viremia
NCT07225972 is registered in ClinicalTrials.gov with New York Medical College as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection/Viremia
- Lead sponsor
- New York Medical College
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 1, 2026
- Completion date
- December 1, 2032
- Enrollment
- 138 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
adenovirus, adv infection, adv reactivation, cmv, cytomegalovirus infections